News

Children as young as 12 can now receive tenofovir alafenamide for treatment of chronic hepatitis B virus infection with compensated liver disease, after the US Food and Drug Administration expanded the indication for the drug.

With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.

A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.

In episode 1 of this short video series, a clinician discusses what types of patients are best suited for inpatient or outpatient care for these infections.

Two patients at a hospital in Australia were administered Thin Film Freezing Voriconazole Inhalation Powder (TFF VORI), which showed treatment efficacy for both patients.

The investigational shot from Pfizer and Valneva demonstrated higher antibody levels in the three-dose vaccination schedule versus the two-dose vaccination schedule.

Ibrexafungerp tablets (Brexafemme) were already FDA approved to treat vulvovaginal candidiasis (VVC) and have now received a second indication for the reduction of recurrent VVC (yeast infection).

Tonight, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product, intended to prevent recurrent C difficile infection in adults.

Resistance to hepatitis C infection may be much greater than previously thought, according to new research by investigators at Trinity College Dublin that revealed associated biological factors.

Alternative strategies to increase immunogenicity of COVID-19 vaccines in immunosuppressed kidney transplant recipients are evaluated in clinical trial.

Takeda’s investigational dengue vaccine TAK-003 is currently under evaluation for preventing any dengue virus serotype in individuals 4-60 years old.

Priorix and M-M-R II are fully interchangeable vaccines to protect against measles, mumps, and rubella, the CDC’s Advisory Committee on Immunization Practices said.

The World Health Organization (WHO) made the announcement today.

Investigators looked at COVID-19 related hospitalizations in infants less than 6 months old who were unable to be vaccinated. The researchers used population-based surveillance for lab-confirmed COVID-19 hospitalizations.

A recent study by investigators at the University of Pittsburgh School of Medicine found few mild adverse events from monoclonal antibody treatment among pregnant people with COVID-19, but no difference in COVID-19 outcomes.

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.

Sanofi and GlaxoSmithKline are the latest companies to bring their COVID-19 booster vaccine to the marketplace with the European Commission’s approval of VidPrevtyn Beta.

An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.

New clinical findings suggest the Pfizer-BioNTech bivalent booster elicited more neutralizing antibody titers for all tested emerging Omicron sublineages, compared to their original COVID-19 vaccine.

Earlier and higher rates of RSV and other respiratory illnesses following reduced COVID precautions challenge capacity of pediatric units.

Read and watch the infectious disease trial data shared this week.

As viral hepatitis is the most common blood-transmitted infection globally, assessing the toll of hepatitis and hepatitis-related conditions is critical.

Dr. Tosin Goje explains the promise of ibrexafungerp for clearing yeast infection and improving quality of life for these patients.

The company says it plans to begin talking with regulators next year after seeing positive efficacy data in the trials.

A clinician offers his perspective on what he sees as a clinician and trial investigator in terms of what is in the pipeline and both the encouraging data and uncertainty in therapy development overall.

Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.

Three posters on the subject were presented at The Liver Meeting and were among the meeting’s key presentation highlights called “Best of the Liver Meeting.”

Although HIV PrEP uptake is gradually increasing, usage remains low among key at-risk populations.

Young women who binge drink, and especially those who use multiple substances, had a higher risk of COVID-19 infection and mental health complications.